These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2680497)

  • 1. Clinical results with oral milrinone in heart failure.
    DiBianco R
    Eur Heart J; 1989 Aug; 10 Suppl C():44-52. PubMed ID: 2680497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic achievements of phosphodiesterase inhibitors and the future.
    Jewitt DE
    Eur Heart J; 1989 Aug; 10 Suppl C():53-9. PubMed ID: 2680498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure.
    DiBianco R; Shabetai R; Kostuk W; Moran J; Schlant RC; Wright R
    N Engl J Med; 1989 Mar; 320(11):677-83. PubMed ID: 2646536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group.
    Packer M; Carver JR; Rodeheffer RJ; Ivanhoe RJ; DiBianco R; Zeldis SM; Hendrix GH; Bommer WJ; Elkayam U; Kukin ML
    N Engl J Med; 1991 Nov; 325(21):1468-75. PubMed ID: 1944425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of phosphodiesterase inhibitors on survival of patients with chronic congestive heart failure.
    Packer M
    Am J Cardiol; 1989 Jan; 63(2):41A-45A. PubMed ID: 2642629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators.
    Colucci WS; Sonnenblick EH; Adams KF; Berk M; Brozena SC; Cowley AJ; Grabicki JM; Kubo SA; LeJemtel T; Littler WA
    J Am Coll Cardiol; 1993 Oct; 22(4 Suppl A):113A-118A. PubMed ID: 8376682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exercise responses before and after long-term treatment with oral milrinone in patients with severe heart failure.
    Ribeiro JP; White HD; Arnold JM; Hartley LH; Colucci WS
    Am J Med; 1986 Nov; 81(5):759-64. PubMed ID: 3535490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter, double-blind study of intravenous milrinone for patients with acute heart failure in Japan. Japan Intravenous Milrinone Investigators.
    Seino Y; Momomura S; Takano T; Hayakawa H; Katoh K
    Crit Care Med; 1996 Sep; 24(9):1490-7. PubMed ID: 8797620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preload-dependent hemodynamic effects of milrinone in moderate heart failure.
    Remme WJ; van Hoogenhuyze DC; Kruijssen HA; Pieper PG; Bruggeling WA
    Cardiology; 1992; 80(2):132-42. PubMed ID: 1611632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a new bipyridine inotropic agent--milrinone--in patients with severe congestive heart failure.
    Baim DS; McDowell AV; Cherniles J; Monrad ES; Parker JA; Edelson J; Braunwald E; Grossman W
    N Engl J Med; 1983 Sep; 309(13):748-56. PubMed ID: 6888453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of patients with severe congestive heart failure treated with oral milrinone.
    Baim DS; Colucci WS; Monrad ES; Smith HS; Wright RF; Lanoue A; Gauthier DF; Ransil BJ; Grossman W; Braunwald E
    J Am Coll Cardiol; 1986 Mar; 7(3):661-70. PubMed ID: 3950244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous milrinone in patients with severe congestive cardiac failure awaiting heart transplantation.
    Skoyles JR; Sherry KM; Price C
    J Cardiothorac Vasc Anesth; 1992 Apr; 6(2):222-5. PubMed ID: 1568013
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: the PROMISE Study.
    Eichhorn EJ; Tandon PK; DiBianco R; Timmis GC; Fenster PE; Shannon J; Packer M
    J Am Coll Cardiol; 1993 Mar; 21(3):634-40. PubMed ID: 8436744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of captopril versus milrinone therapy in modulating the adrenergic nervous system response to exercise in congestive heart failure.
    Corbalán R; Jalil J; Chamorro G; Casanegra P; Valenzuela P
    Am J Cardiol; 1990 Mar; 65(9):644-9. PubMed ID: 2178384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Response to milrinone treatment in patients with chronic congestive heart failure].
    Zeng H; Wen S; Huang D; Liu X; Fang Y
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Jun; 31(2):246-7, 259. PubMed ID: 12515150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Milrinone. A preliminary review of its pharmacological properties and therapeutic use.
    Young RA; Ward A
    Drugs; 1988 Aug; 36(2):158-92. PubMed ID: 3053125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The hemodynamic effects of the combination of milrinone in heart failure refractory to treatment with dopamine, dobutamine and/or nitroprusside].
    Domínguez de Rozas JM; Guindo Soldevila J; Rodríguez Font E; Martínez Vílchez R
    Rev Esp Cardiol; 1994 Oct; 47(10):682-6. PubMed ID: 7991922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous milrinone: therapeutic responses in heart failure.
    Braunwald E
    Am Heart J; 1991 Jun; 121(6 Pt 2):1937-8. PubMed ID: 2035423
    [No Abstract]   [Full Text] [Related]  

  • 19. Controlled and uncontrolled studies of phosphodiesterase III inhibitors in contemporary cardiovascular medicine.
    Hood WB
    Am J Cardiol; 1989 Jan; 63(2):46A-53A. PubMed ID: 2521268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.
    Timmis AD; Smyth P; Jewitt DE
    Br Heart J; 1985 Jul; 54(1):42-7. PubMed ID: 4015915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.